Cumberland PharmaceuticalsCPIX
CPIX
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
9,800% more call options, than puts
Call options by funds: $297K | Put options by funds: $3K
67% more capital invested
Capital invested by funds: $2.61M [Q3] → $4.36M (+$1.75M) [Q4]
1.38% less ownership
Funds ownership: 14.5% [Q3] → 13.12% (-1.38%) [Q4]
9% less funds holding
Funds holding: 22 [Q3] → 20 (-2) [Q4]
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Research analyst outlook
We haven’t received any recent analyst ratings for CPIX.
Financial journalist opinion
Based on 3 articles about CPIX published over the past 30 days
Neutral
PRNewsWire
1 week ago
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
Ifetroban demonstrated significant 5.4% improvement in cardiac function NASHVILLE, Tenn. , March 19, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas.

Neutral
Seeking Alpha
4 weeks ago
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Molly Aggas – Account Supervisor-Dalton Agency A.J. Kazimi – Chief Executive Officer Todd Anthony – Vice President-Organizational Development John Hamm – Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals Fourth Quarter 2024 Financial Report and Company Update.

Neutral
PRNewsWire
4 weeks ago
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval NASHVILLE, Tenn. , March 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.4 million during the fourth quarter of 2024, an 11.6% increase over the prior year period.

Neutral
PRNewsWire
1 month ago
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
NASHVILLE, Tenn. , Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial results and provide a company update after the market closes on Tuesday, March 4, 2025.

Neutral
PRNewsWire
1 month ago
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world's second-largest market NASHVILLE, Tenn. and SHANGHAI , Feb. 18, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") today announced the NMPA (National Medical Products Administration) approval of Cumberland's Vibativ® (telavancin) injection in China.

Positive
Benzinga
1 month ago
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease
On Tuesday, Cumberland Pharmaceuticals Inc. CPIX released topline results from its Phase 2 FIGHT DMD trial.

Neutral
PRNewsWire
1 month ago
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
NASHVILLE, Tenn. , Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial.

Positive
Benzinga
3 months ago
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
On Monday, the FDA approved Cumberland Pharmaceuticals Inc's CPIX supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product.

Neutral
PRNewsWire
3 months ago
FDA APPROVES ACETADOTE® sNDA
- New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn. , Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product.

Neutral
Seeking Alpha
4 months ago
Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon.

Charts implemented using Lightweight Charts™